While it was once considered an exclusion criterion in pivotal trials, transcatheter aortic valve replacement (TAVR) turns out to be a good option for patients with a bicuspid aortic valve (AV). With current-generation devices, procedural, postprocedural, and 1-year outcomes are all comparable following TAVR for bicuspid AV versus tricuspid AV disease.